menu
    • menu
    [{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Endoglin","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Veracyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veracyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Aragon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"||Androgen N-terminal domain receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Boustead Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Boustead Securities"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Boustead Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Boustead Securities"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"PreCheck Health Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ PreCheck Health Services","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ PreCheck Health Services"}]

    Find Clinical Drug Pipeline Developments & Deals for Apalutamide

    Menu

    Apalutamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kairos Announces Completed Enrollment of its Phase 2 Clinical Trial of ENV105

                            Details : ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 31, 2025

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zydus Lifesciences

                            India arrow
                            Hospitalar
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Lifesciences Wins USFDA Nod for Prostate Cancer Drug Production

                            Details : Pryor (apalutamide) is an androgen receptor inhibitor which is indicated for the treatment of patients with prostate cancer.

                            Product Name : Pryor

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

                            Details : ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : PreCheck Health Services

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kairos Partners with PreCheck To Develop Biomarkers For Cancer Drug Resistance

                            Details : The collaboration aims to advance the precision of therapy monitoring for Kairos clinical trials, and to advance cancer treatment by identifying patients who will benefit most from ENV105.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : PreCheck Health Services

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boustead Securities

                            Deal Size : $6.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kairos Pharma Closing of $6.2 Million Initial Public Offering

                            Details : The net proceeds from the offering to fund the company's lead product candidate, ENV105 (carotuximab), which is being evaluated in a mid-stage trial studies for the treatment of prostate cancer.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boustead Securities

                            Deal Size : $6.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boustead Securities

                            Deal Size : $6.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Kairos Pharma Prices $6.2 Million Initial Public Offering

                            Details : The net proceeds from the offering to fund the company's lead product candidate, ENV105 (carotuximab), which is being evaluated in a mid-stage trial studies for the treatment of prostate cancer.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boustead Securities

                            Deal Size : $6.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apalutamide,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Data for ERLEADA Plus ADT Shows 100% Biochemical Free Recurrence Rate Post-Surgery

                            Details : Erleada (apalutamide) is an androgen receptor inhibitor which is being investigated for patients with high-risk locally advanced prostate cancer in combination with androgen deprivation therapy.

                            Product Name : Erleada

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : Apalutamide,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Kairos Pharma

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kairos Doses First Patient in Phase 2 of ENV105 with Apalutamide for Prostate Cancer

                            Details : ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.

                            Product Name : ENV105

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 30, 2024

                            Lead Product(s) : Carotuximab,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Ta...

                            Details : Erleada® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mC...

                            Product Name : Erleada

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            March 04, 2023

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            BDR Pharmaceuticals

                            India arrow
                            Hospitalar
                            Not Confirmed

                            BDR Pharmaceuticals

                            India arrow
                            Hospitalar
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BDR Pharmaceutical Launches Generic Drug for Treating Prostate Cancer in India

                            Details : APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to...

                            Product Name : Apatide

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            March 01, 2023

                            Lead Product(s) : Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth